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Abstract The objective of this study was to evaluate the
efficacy, pharmacokinetics, and safety of adalimumab in
patients with polyarticular juvenile idiopathic arthritis (JIA)
in Japan. Patients aged 4 to 17 years were enrolled in a
single-arm, open-label, multicentre study of adalimumab.
Patients weighing <30 kg received 20 mg every other week
(eow), and those ≥30 kg received 40 mg eow. Concomitant
methotrexate (MTX) was allowed (≤10 mg/m2 per week). The










St. Luke’s International Hospital,
Tokyo, Japan
Y. Itoh
Nippon Medical School Hospital,
Tokyo, Japan
T. Kawai
National Center for Child Health and Development,
Tokyo, Japan
N. Iwata
Aichi Children’s Health and Medical Center,
Aichi, Japan
T. Murata
Osaka Medical College Hospital,
Takatsuki City, Japan
I. Okafuji
Kobe City Medical Center General Hospital,
Hyogo, Japan
M. Miyoshi
Hyogo Prefectural Kobe Children’s Hospital,
Hyogo, Japan
Y. Onoe
National Hospital Organization Kokura Medical Center,
Kitakyushu, Japan
Y. Kawano
Kagoshima University Medical and Dental Hospital,
Kagoshima, Japan
N. Kinjo
Hospital, University of the Ryukyus,
Okinawa, Japan
N. Mozaffarian :G. Patel
Abbott Laboratories,
Abbott Park, IL, USA
H. Kupper










Yokohama City University School of Medicine,
3-9 Fukuura, Kanazawa-ku,
Yokohama, Kanagawa 236-0004, Japan
e-mail: timagawa@ca2.so-net.ne.jp
Clin Rheumatol (2012) 31:1713–1721
DOI 10.1007/s10067-012-2082-5
primary efficacy outcome was the percent of patients
with American College of Rheumatology Pediatric 30
response (ACR Pedi 30) at week 16. JIA core variables,
serum adalimumab concentrations, and anti-adalimumab
antibodies (AAAs) were analysed. Patients were moni-
tored for adverse events (AEs). Twenty-five patients (20
with concomitant MTX at baseline and 5 without) were
enrolled: 24 patients completed 16 weeks of therapy and
22 patients completed 60 weeks. At week 16, 90 % of
patients with MTX and 100 % without MTX achieved
ACR Pedi 30; response rates were maintained through
week 60 in 94 and 80 % of patients, respectively. Each
JIA core variable improved over time. Six patients be-
came AAA positive (two each at weeks 8, 16, and 60),
some of which were transient. All six AAA-positive
patients achieved ACR Pedi 30 at week 16, and four
maintained that response at week 60. Six patients (all
with MTX) experienced nine serious AEs (JIA, pyrexia,
arthralgia, pneumonia, hepatitis B infection, pharyngitis,
dehydration, pharyngeal pain, and pneumonia). In pedi-
atric patients with polyarticular JIA in Japan, adalimu-
mab was safe and effective for reducing disease activity
for up to 60 weeks.
Keywords Adalimumab . Juvenile idiopathic arthritis .
Methotrexate . Pharmacokinetics
Introduction
Juvenile idiopathic arthritis (JIA) is the most common rheu-
matic disease in children <16 years of age [1] and often
causes significant pain, functional impairment, and dimin-
ished health-related quality of life [2–5]. The incidence of
JIA in Japan is estimated to be 10 to 15 per 100,000 children
[6]. The overall incidence in developed countries is estimat-
ed to range from 16 to 150 per 100,000 children [1]. Of the
JIA subtypes, the incidence of polyarticular JIA, which
affects five or more joints, has been reported to be relatively
high among children in Japan, whereas pauciarticular JIA,
which affects four or less joints, is more common in Europe
and the USA [6].
The Pediatric Standing Committee of the Japan College
of Rheumatology and the Pediatric Rheumatology Associa-
tion of Japan collaborated to produce guidelines for the
diagnosis and treatment of JIA in Japan, with an emphasis
on the involvement of pediatric rheumatologists, early in-
tervention, and individualised therapy [6]. For articular JIA,
nonsteroidal anti-inflammatory drugs (NSAIDs) are the
first-line therapy of choice, followed by disease-modifying
antirheumatic drugs (DMARDs) such as methotrexate
(MTX) and oral corticosteroids [6]. Patients with JIA often
have persistent disease. Consequently, the use of these
agents may be limited by long-term toxicity, including po-
tential effects on growth, partial/inadequate responses, and
inability to maintain disease remission [7–9]. Short-term
toxicities and drug intolerance are also an issue in this
population. Some patients with JIA may benefit from treat-
ment with biologic agents. Further guidance on this topic
was recently published by the American College of Rheu-
matology (ACR) and is under development elsewhere [10,
11]. Availability of biologic therapies, including the anti-
tumour necrosis factor (anti-TNF) agents adalimumab, eta-
nercept, and infliximab, the T-cell inhibitor abatacept, and
the humanised anti-human interleukin 6 receptor monoclo-
nal antibody tocilizumab, represents a major advancement
in the treatment of rheumatic diseases. Of these agents,
etanercept, tocilizumab, and adalimumab are approved for
JIA in Japan [11–13].
Adalimumab is a fully human monoclonal antibody spe-
cific to human TNF-alpha that is approved in the USA
(February 2008) and Europe (September 2008) for the treat-
ment of polyarticular JIA and was recently approved for JIA
in Japan [13–15]. TNF, involved in normal inflammatory
and immune responses, is also elevated in the synovial fluid
of JIA patients. Adalimumab binds specifically to TNF-
alpha and blocks its interaction with cell surface TNF recep-
tors. The relationship between the pharmacodynamic action
of adalimumab and the mechanism(s) by which adalimumab
exerts its clinical effects is unknown but has been hypothe-
sized to involve significant inhibition of the pathologic
inflammatory process. Adalimumab has been shown to be
safe and effective in patients with JIA when dosed every
other week (eow) for up to 3 years in Western populations
[16]. Further, these patients maintained clinical responses
and improvements in disease activity for up to 6 years, with
no deaths or malignancies reported [17]. The primary ob-
jective of this study was to evaluate the efficacy, pharmaco-
kinetics, and safety of adalimumab therapy in pediatric




Pediatric patients aged 4 to 17 years with a diagnosis of
polyarticular JIA by ACR criteria at screening, and active
disease defined as five or more swollen joints (not due
to deformity) and three or more joints with limitation of
passive motion due to pain and/or pain by pressure
(tenderness), were eligible. Patients could have had system-
ic, polyarticular, or pauciarticular JIA at disease onset but
were required to be free of any systemic JIA manifestations
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for at least 12 weeks before screening. All patients were to
have had inadequate clinical response (or intolerance) to
NSAIDs or MTX (8–10 mg per 1 m2 of body surface area
per week for 12 weeks or more), or other conventional
therapies for JIA such as corticosteroids. Negative urine
pregnancy tests at screening and baseline were required for
all postpubertal females; use of adequate contraception dur-
ing the study and for 150 days after last injection was
required for all sexually active patients.
Main exclusion criteria
Patients with a history of or comorbid inflammatory joint
disease other than JIA, including psoriatic arthritis, arthritis
related to enthesopathy, and systematic lupus erythemato-
sus, were excluded. Patients classified as functional class IV
by ACR criteria, prior treatment with alkylating agents or
biologic therapies for JIA, joint surgery within 8 weeks prior
to screening, or articular corticosteroids or sodium hyaluro-
nate within 28 days prior to baseline were also excluded.
Other exclusion criteria included the following: significant
cardiac disease; abnormal laboratory values; positive serol-
ogy for anti-human immunodeficiency virus antibody, hep-
atitis B surface antigen, or hepatitis C antibody; history of a
central nervous system (CNS) neoplasm; active CNS infec-
tion, demyelinating disease, degenerative neurological dis-
ease, or any progressive CNS disease; ongoing chronic or
active infection or any major episode of infection requiring
hospitalisation or treatment with intravenous antibiotics
within 28 days or oral antibiotics within 14 days prior to
screening; history of Listeria infection; tuberculosis con-
firmed by chest X-ray or chest computed tomography at
screening or confirmed history of tuberculosis; history of
cancer, lymphoma, leukemia, or lymphoproliferative disease
other than a successfully treated nonmetastatic cutaneous
squamous cell or basal cell carcinoma and/or localised car-
cinoma in situ of the cervix; and vaccination with a live
vaccine within 12 weeks of study drug administration
through 70 days of the last dose.
Approved/prohibited medications
MTX was either to be discontinued at least 14 days prior to
baseline or, for patients receiving a stable dose (≤10 mg/m2
per week) for ≥12 weeks prior to baseline, could be contin-
ued at the stable dose until week 16. After week 16, dose
reduction or discontinuation of MTX was permitted based
on investigator’s judgement. If MTX was reduced or inter-
rupted, it could subsequently be increased or restarted as
long as the dose was ≤10 mg/m2 per week.
DMARDs other than MTX were to be discontinued at
least 28 days before baseline. NSAIDs or low-dose cortico-
steroids (≤0.2 mg/kg of prednisone per day, up to a
maximum of 10 mg/day, including subcutaneous or intra-
muscular injection) were permitted at stable doses. Pain
medications were not to be taken within 12 h prior to the
study visit joint evaluation. Intraarticular injection of corti-
costeroids or sodium hyaluronate was prohibited until
week 16, after which time, one intraarticular injection of
corticosteroid or sodium hyaluronate was permitted; how-
ever, the joint was considered nonevaluable for 12 weeks
after injection. Use of immunosuppressants or leukocyta-
pheresis, alkylating agents such as cyclophosphamide, and
analgesic opium alkaloid/synthetic narcotics was prohibited.
Study design and ethics
This single-arm, open-label, multicentre study evaluating the
efficacy, pharmacokinetics, and safety of fixed dose adalimu-
mab in pediatric patients with polyarticular JIAwas conducted
at 14 sites in Japan from May 2008 to August 2010
(NCT00690573). After a 2- to 4-week screening period,
patients received subcutaneous adalimumab injections eow.
Based on pharmacokinetic simulations performed using body
surface area-dependent dosing data from aWestern (USA and
Europe) clinical JIA study (NCT00048542) [16], a fixed dose
dosing regimen was established in which two different doses
of adalimumab were administered based on body weight.
Patients weighing <30 kg received adalimumab 20 mg eow
and patients weighing ≥30 kg received adalimumab 40 mg
eow. Adalimumab dosage was re-evaluated based on actual
body weight at week 16 and every 12 weeks after week 24
through week 60.
The study was conducted in accordance with the Decla-
ration of Helsinki. In accordance with harmonised good
clinical practices, institutional review boards approved the
study protocol and the informed consent form. The patient
or parent or legal guardian of the patient reviewed and
voluntarily signed the informed consent form prior to in-
volvement in any study-related procedures.
Clinical assessments
Clinical measures were assessed at weeks 2, 4, 8, 16, and 24
and every 12 weeks after week 24. The following JIA core
criteria were used to calculate ACR Pedi scores: Physician’s
Global Assessment of disease activity (PhGA), Patient’s
Global Assessment of well-being (PaGA), active joint count
in 73 joints (AJC73), limitation of motion in 69 joints
(LOM69), Childhood Health Assessment Questionnaire
(CHAQ) to assess physical function, and C-reactive protein
(CRP) concentration. ACR Pediatric 30 (ACR Pedi 30)
response was defined as ≥30 % improvement in at least
three of six JIA core criteria and ≥30 % worsening in not
more than one of six JIA core criteria. ACR Pedi 50/70/90
responses were defined similarly according to the respective
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level of response for at least three of the six JIA core criteria
and ≥30 % worsening in not more than one of six JIA core
criteria.
Pharmacokinetics and immunogenicity
Blood samples for analysis of serum adalimumab con-
centrations and anti-adalimumab antibodies (AAAs)
were collected at baseline and weeks 2, 4, 8, 16, 24,
36, 48, and 60. A validated enzyme-linked immunoad-
sorbent assay method based on a double-antigen tech-
nique was used to measure adalimumab and AAA
concentrations. The lower limit of quantitation (LLOQ)
for adalimumab was 3.13 ng/mL in diluted (1:10) serum
or 31.3 ng/mL in undiluted serum. The LLOQ for
AAAs was 1.0 ng/mL in diluted serum or 10 ng/mL
in undiluted serum. Samples were considered AAA-
positive if the measured AAA concentration was
>20 ng/mL in undiluted serum, and the sample was
collected within 30 days after an adalimumab dose.
Serum samples with adalimumab concentrations >2 μg/
mL were not analysed for AAAs.
Safety
The investigator monitored each patient for clinical and
laboratory evidence of adverse events (AEs) on a routine
basis throughout the study. AEs were also assessed at a
follow-up visit 28 days after study completion and 70 days
after the last dose of study drug (by site visit or telephone).
Duration of exposure was calculated as the number of days
between the first dose of study drug and the last dose plus
14 days.
Statistical analysis
As per the prespecified analysis plan, efficacy analyses
were conducted on the full analysis set, which was
defined as all patients who received at least one dose
of study drug. The primary efficacy endpoint, ACR Pedi
30 response rate at week 16, was analysed with non-
responder imputation (NRI), whereby patients with
missing data at week 16 or who failed to meet ACR
Pedi 30 response at week 16 were considered non-
responders. Secondary endpoints, including longitudinal
data for ACR Pedi 30/50/70/90 response rates and the
JIA core variables from week 16 through week 60, were
analysed using observed cases (i.e., only patients who
were in the study at the time point being evaluated were
included). Serum adalimumab and AAA concentrations
were summarised descriptively. The numbers and per-
centages of patients who experienced AEs with an onset
on or after the first adalimumab injection up to 70 days
(five half-lives) after the last injection were summarised
for the safety analysis set, which was identical to the
full analysis set.
Table 1 Demographics and
clinical characteristics at baseline
AJC active joint count, CCP cy-
clic citrullinated protein, CHAQ
Childhood Health Assessment
Questionnaire, CRP C-reactive
protein, JIA juvenile idiopathic
arthritis, LOM limitation of mo-
tion, MTX methotrexate, PaGA
Patient’s Global Assessment,
PhGA Physician’s Global As-
sessment, RF rheumatoid factor,
SD standard deviation
With MTX Without MTX All adalimumab
(N020) (N05) (N025)
Age
Mean (SD), years 13.2 (3.22) 12.6 (4.39) 13.0 (3.38)
4–12 years, n (%) 9 (45) 3 (60) 12 (48)
13–17 years, n (%) 11 (55) 2 (40) 13 (52)
Female, n (%) 15 (75) 5 (100) 20 (80)
Body weight
Mean (SD), kg 40.5 (11.28) 35.3 (16.64) 39.5 (12.31)
≥30 kg, n (%) 14 (70) 3 (60) 17 (68)
Duration of JIA, mean (SD), years 4.8 (3.97) 4.2 (2.75) 4.7 (3.72)
RF positive, n (%) 14 (70) 3 (60) 17 (68)
Anti-CCP antibody, mean (SD), U/mL 105.5 (135.67) 8.5 (15.50) 86.1 (127.19)
LOM69, mean (SD) 8.6 (5.65) 5.8 (2.05) 8.0 (5.22)
AJC73, mean (SD) 12.0 (6.10) 13.6 (9.32) 12.3 (6.66)
CRP concentration
Abnormal (>0.3 mg/dL), n (%) 11 (55) 3 (60) 14 (56)
Mean (SD), mg/dL 1.0 (1.32) 3.6 (3.86) 1.5 (2.22)
CHAQ (0–3), mean (SD) 0.8 (0.79) 0.7 (1.11) 0.8 (0.84)
PhGA (0–100 mm), mean (SD) 56.5 (18.49) 58.6 (25.83) 56.9 (19.56)
PaGA (0–100 mm), mean (SD) 44.6 (24.84) 48.6 (34.20) 45.4 (26.19)
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Results
Patient disposition and duration of treatment
A total of 25 children with JIA were treated with adalimu-
mab, of which 20 were receiving concomitant MTX at
baseline. Twenty-four patients completed 24 weeks of ther-
apy, including the primary endpoint assessment at week 16,
and 22 patients completed up to 60 weeks. The three
patients who discontinued the study, all due to lack of
efficacy, were in the concomitant MTX group. The average
duration of adalimumab treatment through week 60 was
396 days (390 days for patients receiving concomitant
MTX at baseline and 421 days for patients without MTX).
Baseline demographics and clinical characteristics
At baseline, the mean age was approximately 13 years, 80 %
of the patients were female, and 32 % weighed <30 kg
(Table 1). For patients who received MTX (N020) and those
who did not (N05), respectively, the duration of JIAwas 4.8
and 4.2 years, 70 and 60 % were rheumatoid factor positive
(RF positive), and 55 and 60 % had abnormal (>3 mg/dL)
CRP concentrations. All patients had polyarticular JIA at
disease onset, except for one patient (not receiving MTX)
who had pauciarticular JIA at disease onset.
Baseline PhGA, PaGA, and CHAQ scores were similar
between groups. Baseline anti-cyclic citrullinated protein
(anti-CCP) antibody concentrations were considerably
greater in patients who were receiving MTX compared with
Fig. 1 ACR Pedi 30 response rates. a Primary efficacy outcome: ACR
Pedi 30 response rates at week 16 of adalimumab therapy (NRI). b
ACR Pedi 30 response rates over time with adalimumab therapy (as
observed) (black diamond with MTX, grey circle without MTX)
Table 2 JIA core variables at weeks 16 and 60 of adalimumab therapy (as observed)
Adalimumab with MTX Adalimumab without MTX
Mean baseline value Mean visit value Mean % change Mean baseline value Mean visit value Mean % change
Week 16
PhGA (mm) 55.8 20.6 −64.8 58.6 10.6 −83.8
PaGA (mm) 44.7 22.1 −50.5 48.6 15.4 −74.5
AJC73 11.0 3.8 −59.9 13.6 3.2 −80.3
LOM69 7.5 3.7 −38.3 5.8 1.6 −76.7
CHAQ 0.7 0.4 −32.8 0.7 0.4 −35.7
CRP (mg/dL) 0.9 0.3 −23.8 3.6 1.7 −65.1
Week 60
PhGA (mm) 55.0 16.7 −74.0 58.6 12.8 −81.5
PaGA (mm) 42.9 16.6 −51.7 48.6 27.0 −48.6
AJC73 11.1 1.9 −81.5 13.6 3.0 −79.8
LOM69 7.6 1.5 −78.7 5.8 2.4 −72.2
CHAQ 0.7 0.2 −46.9 0.7 0.5 −41.0
CRP (mg/dL) 1.0 0.4 −46.6 3.6 1.4 −4.0
AJC active joint count, CHAQ Childhood Health Assessment Questionnaire, CRP C-reactive protein, LOM limitation of motion, MTX methotrex-
ate, PaGA Patient’s Global Assessment, PhGA, Physician’s Global Assessment
Clin Rheumatol (2012) 31:1713–1721 1717
those not receivingMTX. All patients had received DMARDs
previously. At baseline, all patients were receiving concomi-
tant NSAIDs, and most patients were also receiving concom-
itant systemic corticosteroids (70 % in the MTX group and
80 % in the non-MTX group).
Efficacy
Primary endpoint: ACR Pedi 30 response
Overall, 92 % of patients achieved ACR Pedi 30 at week16
of adalimumab therapy (90 % in the MTX group and 100 %
in the non-MTX group) (Fig. 1a). ACR Pedi 30 response at
week 60 was observed for 94 % of patients with concomi-
tant MTX and 80 % of patients without concomitant MTX
(Fig. 1b).
ACR Pedi 50/70/90 responses
ACR Pedi 50/70 response rates at week 16 of adalimumab
therapy were generally consistent with those at week 60,
with approximately 90 and 75 % of patients achieving these
levels of response. Overall, ACR Pedi 90 response rates
increased from ≤20 % at week 16 to 50 % at week 60.
JIA core variables over time
Adalimumab therapy was associated with improvements in
each of the six JIA core variables over time (Table 2). Mean
decreases in disease activity generally started as early as
week 2 (data not shown) and remained consistent with
improvements observed through week 60.
Pharmacokinetics and immunogenicity
Mean adalimumab concentrations for patients who received
adalimumab 40 mg eow plus MTX were 10.4 μg/mL (range,
0–19.4 μg/mL; N014) at week 16 and 14.4 μg/mL (range, 0–
21.6 μg/mL; N014) at week 60 (Fig. 2a). Mean adalimumab
concentrations for patients who received adalimumab 20 mg
eow plus MTXwere 6.73 μg/mL (range, 0–13.2 μg/mL; N06)
at week 16 and 14.3 μg/mL (range, 0–24.6 μg/mL; N06) at
week 60; two of the six patients initially receiving the 20-mg
dosage increased to 40 mg by week 60 due to changes in body
weight. For patients receiving adalimumab without MTX,
mean adalimumab concentrations were consistent with mean
concentrations in patients receiving adalimumab plus MTX
(Fig. 2b).
At week 24 of adalimumab therapy, 16 % (4 of 25) patients
had at least one AAA-positive serum sample (3 of 20 with
MTX [15 %] and 1 of 5 without MTX [20 %]). At week 60,
15 % (3 of 20) of patients receiving adalimumab plus MTX
and 60 % (3 of 5) of patients receiving adalimumab without
MTX had detectable AAAs (6 of 25 patients [24 %] overall).
Two patients first had detectable AAAs at week 8, two at
week 16, and two at week 60. Of these six patients, three
patients were receiving the 20-mg dosage (one with MTX and
two without MTX) and three were receiving the 40 mg dosage
(two with MTX and one without MTX).
Trough concentrations of adalimumab <2 g/mL were tran-
sient for three of the four patients in whom AAAs were
detected prior to week 60. For two of these four patients
(one with MTX and one without MTX), the lack of
Fig. 2 Serum adalimumab concentrations. a Mean concentration for
all patients (N020) with concomitant MTX by dosage of adalimumab
(black circle 20 mg eow, open circle 40 mg eow). b Mean concentra-
tion in patients without concomitant MTX (N05) by dosage of adali-
mumab (black circle 20 mg eow, open circle 40 mg eow). Asterisk
Adalimumab dosages were increased from 20 to 40 mg eow at week 16
for two patients, at week 36 for one patient, and at week 48 for one
patient owing to body weight increases (<30 kg at baseline to ≥30 kg at
week 16), as per protocol
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measurable serum adalimumab at a given study visit was
followed by detectable adalimumab concentrations that in-
creased at later time points through week 60. Another patient
(withMTX) had AAAs detected at week 8 but had measurable
adalimumab concentrations at weeks 36 and 48 following
dosage increase to 40 mg eow at week 16; the patient’s
adalimumab concentration was again undetectable at week 60.
The remaining patient (with MTX) had undetectable adalimu-
mab concentrations from week 8 to week 60. All six patients
with AAA at any time point achieved ACR Pedi 30 response
at week 16 and completed the study; four of the six patients
exhibited ACR Pedi 30 response at week 60.
Safety
Through week 60, all patients had experienced at least one AE
(Table 3). Six patients (all with concurrent MTX) experienced
nine serious AEs as follows: JIA, pyrexia, and arthralgia;
pneumonia; hepatitis B infection; pharyngitis; dehydration,
pharyngeal pain, and pyrexia. Consistent with study exclusion
criteria, the patient with hepatitis B infection had been negative
for hepatitis Bs antigen and antibodies against HBs and HBc at
the start of the trial; no risk factors for transmission (i.e., travel
to endemic areas, injection drug use, or other exposure) were
reported, and the patient discontinued the study because of this
event. Of the six patients with serious AEs, four occurred in
AAA-negative patients and two occurred in AAA-positive
patients (one with serious AE of JIA; one with serious AEs
of dehydration, pharyngeal pain, and pneumonia).
AEs of special interest
Infections occurred in 80 % of patients receiving MTX and
100 % of patients not receiving MTX, of which three in the
MTX group were serious (acute pharyngitis, pneumonia, and
hepatitis B infection). Six patients had an injection-site reac-
tion (erythema, swelling, warmth, all in the MTX group) and
three had a hepatic event (two in the MTX group, hepatic
function abnormal and blood alkaline phosphatase increased;
one in the non-MTX group, hepatic function abnormal). No
deaths, malignancies, opportunistic infections, congestive
heart failure, demyelinating disease, allergic reactions, lupus-
like syndrome, or blood dyscrasias were reported in any
patient through week 60 of the study.
Discussion
Polyarticular JIA with RF positivity, which represents ap-
proximately 5 % of patients with JIA, tends to be more
aggressive than RF-negative polyarticular JIA and is asso-
ciated with early joint destruction and disability [18, 19]. In
addition, RF-positive JIA patients have been found to be
less likely to achieve a state of disease inactivity and spend
more time in an active disease state compared with RF-
negative patients [20]. In the present study, 68 % of patients
were RF positive, thus representing a population of patients
with potentially severe and difficult-to-treat JIA who are
candidates for intensive therapy. Results of this study dem-
onstrate the efficacy of adalimumab in reducing disease
activity and maintaining response through 60 weeks of
therapy in pediatric patients with polyarticular JIA in Japan.
Because the majority of patients in the study were receiving
concomitant MTX, firm conclusions regarding the efficacy
of adalimumab monotherapy vs. combination therapy are
limited; however, adalimumab-treated patients receiving
combination therapy with MTX in the Western JIA study
had numerically higher ACR Pedi 30, 50, 70, and 90
responses compared with those not receiving MTX [16].
AAAs may develop in some patients during adalimumab
therapy. In pediatric patients with JIA in Japan, an AAA-
positive result was not associated with study discontinuation
or lack of efficacy; all six patients with AAAs completed the
study, and four achieved at least ACR Pedi 30 at week 60.
AAA positive rates in pediatric patients on concomitant
MTX were numerically different, with a higher rate in
Table 3 Patients with treatment-
emergent adverse events
AE adverse event, MTX
methotrexate
Adverse Event Adalimumab with MTX Adalimumab without MTX All adalimumab
(N020) (N05) (N025)
n (%) n (%) n (%)
Any AE 20 (100) 5 (100) 25 (100)
Any severe AE 0 0 0
Any AE leading to
discontinuation of study drug
1 (5) 0 1 (4)
Any serious AE 6 (30) 0 6 (24)
Any infectious AE 16 (80) 5 (100) 21 (84)
Any serious infectious AE 3 (15) 0 3 (12)
Injection-site reaction 6 (30) 0 6 (24)
Hepatic-related AE 2 (10) 1 (20) 3 (12)
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Japanese vs. Western patients, 15 % (3/20) vs. 5.9 % (5/85),
respectively [16]. JIA rates appear consistent with rates
observed in Japanese and Western adult RA populations;
however, limited pediatric data preclude any correlation
with adult RA. In this study, the overall sample size, partic-
ularly of the non-MTX group, was too small to make any
meaningful comparison of AAA rates to the Western JIA
study population.
The similarity of the inclusion criteria between the present
study conducted in Japan and the Western JIA study [16]
allows for comparison of the results. Disease duration (approx-
imately 4 years) and baseline JIA core criteria generally were
similar between patients in both studies; however, a greater
percentage of patients in Japan were RF positive at baseline
and had received prior DMARD therapy. Notably, ACR Pedi
30 rates at week 16 for patients receiving adalimumab plus
MTX were comparable between both studies, with >90 % of
patients in each study achieving this efficacy endpoint.
In adult RA, the overall safety profile of adalimumab in
Japanese studies is consistent with that observed in Western
studies [21–23]. Similarly, the safety profile of adalimumab in
patients with polyarticular JIA in Japan was as expected,
based on the safety profile observed in the Western JIA study
[16], and no new AEs of interest were observed. Although
infections were the most commonAE of interest in the present
study, no opportunistic infections or tuberculosis were
reported through 60 weeks of adalimumab therapy. One event
of hepatitis B infection was reported in the present study, and
hepatitis B evaluation is recommended for patients receiving
biologic therapy.
In addition to adalimumab, two other biologic agents
(etanercept and tocilizumab) are approved for the treatment
of JIA in Japan. Although head-to-head trials have not been
conducted, clinical efficacy as measured by ACR Pedi 30
response rates appears to be relatively similar among these
drugs. In a study of DMARD-refractory polyarticular JIA in
Japan, etanercept treatment resulted in an ACR Pedi 30
response rate of 91 % at week 12 of the primary study and
94 % at week 96 of the open-label extension [12]. For the
anti-interleukin-6 receptor antibody tocilizumab, approved
for DMARD-refractory polyarticular JIA and systemic JIA
[11], the ACR Pedi 30 response rate was 95 % at week 12
and 100 % at week 48 [24].
Limitations of this study include the open-label study de-
sign and small sample size, especially for patients not receiv-
ing MTX. In addition, the effect of adalimumab on
radiographic progression could not be assessed because X-
ray data were not collected. Although the absence of valid and
reliable radiographic scoring systems in children with JIA is
the primary reason radiographic outcomes have not been
included in pivotal JIA trials, measures such as the adapted
Sharp-van der Heijde score have been validated and are rec-
ommended for use in future pediatric JIA studies [25, 26].
The efficacy, safety, and tolerability of adalimumab were
demonstrated and maintained through 60 weeks of therapy
in patients with JIA in Japan. The results of the present
study were similar to those from a JIA study conducted in
the USA and Europe [16]. AAA-positive rates were numer-
ically greater in JIA patients in Japan; however, the devel-
opment of these antibodies was not associated with study
discontinuation or with lack of efficacy. In conclusion,
fixed-dose adalimumab (20 or 40 mg eow) was effective
in reducing disease activity in pediatric patients with poly-
articular JIA in Japan.
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